0000000000957857

AUTHOR

Guido Pastore

showing 4 related works from this author

The outcome of Wilms' tumor in infants. Italy 1970-79.

1982

Thirty-four infants under 1 year of age with Wilms’ tumor were diagnosed and treated in 14 Italian pediatric oncology units during 1970-79. The 3-year survival rates decreased with higher group unilateral tumors: 95% in group I Wilms’ tumor, 75% in group II and 20% in group III. The survival rates for children with group I and II Wilms’ tumor were similar for those who were treated with surgery and chemotherapy and those who also received postoperative radiotherapy. During 1975-79 fewer patients with group I Wilms’ tumor received radiotherapy (1 of 11) than during 1970-74 (4 of 6, p < 0.05). All these children are alive at this writing.

MaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentGroup iiPostoperative radiotherapyWilms TumormedicinePediatric oncologyHumansRetrospective StudiesChemotherapybusiness.industryInfant NewbornInfantWilms' tumorRetrospective cohort studyGeneral Medicinemedicine.diseaseInfant newbornKidney NeoplasmsSurgeryRadiation therapyOncologyItalyFemalebusiness
researchProduct

Italian registry of patients off therapy after childhood acute lymphoblastic leukemia. Results after first phase of data collection

1986

The Italian Registry of Off-Therapy patients after childhood tumors now includes 760 subjects with acute lymphoblastic leukemia. These patients were all removed from treatment by December 31, 1981, and were followed in 35 different institutions. All the children have received multiple-drug treatment, combined, in 79.7% of the cases, with cranial irradiation. Thirty-nine (5%) experienced a relapse before treatment suspension. Total duration of antileukemic therapy ranges between 18 and 131 months (median, 38). At the last updating (December 31, 1981), 699 subjects were alive, 6 were lost to follow-up, and 55 had died. Life-table analysis shows that 90.8% were alive and 77% were alive in cont…

Cancer Researchmedicine.medical_specialtyPediatricsbusiness.industryLymphoblastic Leukemiamedicine.diseaseOncologyEl NiñoMale patientAcute lymphocytic leukemiaEpidemiologyFemale patientmedicinebusinessChildhood Acute Lymphoblastic LeukemiaAfter treatmentCancer
researchProduct

Italian cancer figures, report 2013: Multiple tumours

2013

This collaborative study, based on data collected by the network of Italian association of cancer registries (AIRTUM), provides updated estimates on the incidence risk of multiple primary cancer (MP). The objective is to highlight and quantify the bidirectional associations between different oncological diseases. The quantification of the excess or decreased risk of further cancers in cancer patients, in comparison with the general population, may contribute to understand the aetiology of cancer and to address clinical follow-up.Data herein presented were provided by AIRTUM population-based cancer registries, which cover nowadays 48% of the Italian population. This monograph utilizes the AI…

AdultMaleData Interpretationcancer incidenceAdolescentEpidemiologySettore MED/42 - Igiene Generale E ApplicataNeoplasms Multiple PrimaryCohort StudiesYoung AdultMultiple PrimaryRisk FactorsNeoplasms80 and overHumansChildPreschoolAgedRetrospective StudiesAged 80 and overIncidenceEnvironmental and Occupational Healthmultiple tumourInfantNeoplasms Second Primaryitalian cancer; multiple tumours; cancer incidenceStatisticalMiddle Ageditalian cancerMultiple primary cancer incidenceAdolescent; Adult; Aged; Aged 80 and over; Child; Child Preschool; Cohort Studies; Data Interpretation Statistical; Female; Humans; Incidence; Infant; Italy; Male; Middle Aged; Neoplasms Multiple Primary; Neoplasms Second Primary; Retrospective Studies; Risk Factors; Young AdultSecond PrimaryItalyChild PreschoolData Interpretation StatisticalEpidemiology; Public Health Environmental and Occupational HealthFemalePublic Health
researchProduct

Survival of European children and young adults with cancer diagnosed 1995-2002

2009

This study analyses survival in 40,392 children (age 0-14 years) and 30,187 adolescents/young adults (age 15-24 years) diagnosed with cancer between 1995 and 2002. The cases were from 83 European population-based cancer registries in 23 countries participating in EUROCARE-4. Five-year survival in countries and in regional groupings of countries was compared for all cancers combined and for major cancers. Survival for 15 rare cancers in children was also analysed. Five-year survival for all cancers combined was 81% in children and 87% in adolescents/young adults. Between-country survival differences narrowed for both children and adolescents/young adults. Relative risk of death reduced signi…

MaleCancer ResearchPediatricsMESH : Child PreschoolAdolescentsMESH: Epidemiologic Methods[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineMESH : ChildNeoplasmsMESH: ChildEpidemiologyMESH: NeoplasmsMESH : Female030212 general & internal medicineYoung adultChildChildrenChildren & young adults; Cancer survivalMESH : InfantPopulation-based cancer registriesChildren & young adultsMESH: Infant3. Good healthEuropeEastern europeanOncologyMESH: Young AdultChild Preschool030220 oncology & carcinogenesisMESH : Rare DiseasesRare tumoursFemaleMESH: Rare Diseasesmedicine.medical_specialtyAdolescentMESH : MaleMESH : EuropeMESH : Young AdultSocio-culturale[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Epidemiologic MethodsYoung Adult03 medical and health sciencesRare DiseasesSDG 3 - Good Health and Well-beingMESH : AdolescentmedicineHumansPreschoolAdolescents; Cancer survival; Children; Europe; Population-based cancer registries; Rare tumours; Young adults; Adolescent; Child; Child Preschool; Epidemiologic Methods; Europe; Female; Humans; Infant; Male; Neoplasms; Rare Diseases; Young Adult; Oncology; Cancer ResearchSurvival analysisMESH: AdolescentMESH: Humansbusiness.industryMESH: Child PreschoolMESH : HumansInfantCancermedicine.diseaseMESH : NeoplasmsCancer survivalMESH: MaleCancer registryEl NiñoRelative riskMESH: EuropeEpidemiologic MethodsbusinessMESH: FemaleYoung adults
researchProduct